Effect of atorvastatin and clopidogrel on cellular immune function

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 68, Issue 3, 2003, Pages 251-255

  Kroger K ^a   Lindemann, M ^b   Kreuzfelder, E ^b   Brocker M ^b   Santosa, F ^a   Grosse Wilde, H ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b NONE

Author keywords

Apoptose; Atorvastatin; Cellular immune reponse; Clopidogrel; Lymphocyte subpopulation

Indexed keywords

ANNEXIN; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; AZATHIOPRINE; CD69 ANTIGEN; CD86 ANTIGEN; CHOLESTEROL; CLOPIDOGREL; CONCANAMYCIN A; FAS ANTIGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HLA DR ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOGENIC AGENT; OKT 3; PHYTOHEMAGGLUTININ; PLASMINOGEN ACTIVATOR INHIBITOR; POKEWEED MITOGEN; PREDNISONE; TRIACYLGLYCEROL;

ADULT; APOPTOSIS; ARTICLE; CELLULAR IMMUNITY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LIPID BLOOD LEVEL; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE COUNT; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION INHIBITORS; PYRROLES; TICLOPIDINE;

EID: 0037372337     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(02)00278-8     Document Type: Article

References (23)

1. F.R. Verhoeye, O. Descamps, B. Husson, J.C. Honedekijn, M.F. Ronveaux-Dupal, J.F. Lontie, F.R. Heller, An improved method for detection of low density lipoprotein receptor defects in human lymphocytes, J. Lipid Res. 37 (1996) 1377-1384.
2. L.A. Bolkhova, I.V. Fuki, E. Solov'eva, V.A. Koshechkin, V.S. Repin, The cholesterol level in the peripheral blood lymphocytes, Biull. Eksp. Biol. Med. 116 (1993) 476-479.
3. B. Raungaard, J.U. Borholt-Petersen, H.K. Jensen, O. Faegemann, Flow cytometric assessment of effects of fluvastatin on low-density lipoprotein receptor activity in stimulated T-lymphocytes from patients with heterozygous familial hypercholesterolemia, J. Clin. Pharmacol. 40 (2000) 421-429.
4. S. Bellosta, D. Via, M. Canavesi, P. Pfister, R. Fumagalli, R. Paoletti, F. Bernini, HMG-COA reductase inhibitors reduce MMP-9 secretion by macrophages, Arterioscler. Thromb. Vasc. Biol. 18 (1995) 1671-1678.
5. S. Katznelson, X.M. Wang, D. Chia, M. Ozawa, H.P. Zhong, M. Hirata, P.I. Teraska, J.A. Kobashigawa, The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro, J. Heart Lung Transplant. 17 (1998) 335-340.
6. C.A. Dujovne, W.S. Harris, R. Altman, R.W. Overhiser, D.M. Black, Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients, Am. J. Cardiol. 85 (2000) 350-353.
7. G. Huhle, C. Abletshauser, N. Mayer, G. Weidinger, J. Harenberg, D.L. Heen, Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA reductase inhibitor, Thromb. Res. 95 (1999) 229-234.
8. T.M. Chused, S. Apasov, M. Sitkovsky, T. Murine, Lymphocytes modulate activity of an ATP-activated P2Z-type purinoceptor during differentiation, J. Immunol. 157 (1996) 1371-1380.
9. S. Katznelson, Immunosuppresive and antiproliferative effects on HMG-CoA reductase inhibitors, Transplant. Proc. 31 (Suppl B) (1999) 22s-24s.
10. J.L. Cutts, T.J. Scallen, J. Watson, A.D. Bankhurst, Role of mevalonic acid in the regulation of natural killer cell cytotoxicity, Cell Physiol. 139 (1989) 550-557.
11. J.L. Cutts, A.D. Bankhurst, Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin, Int. J. Immunopharrnac. 11 (1989) 863-869.
12. S.M. Rudich, P.K. Mongini, R.V. Perez, S. Katznelson, HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation, Transplant. Proc. 30 (1998) 992-995.
13. S. Kurakata, M. Kada, Y. Shimada, T. Komai, K. Nomoto, Effects of different inhibitors 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase pravastatin sodium and simvastatin on sterol synthesis and immunological functions in human lymphocytes in vitro, Immunopharmacology 34 (1996) 51-61.
14. B. Kwak, F. Mulhaupt, S. Myit, F. Mach, Statins as a newly recognized type of immunomodulator, Nature Med. 6 (2000) 1399-1402.
15. K. Senior, The hidden potential of statins, Lancet 256 (2000) 1906.
16. A. Berger, Statins could be useful in organ transplantation, BMJ 321 (2000) 1430.
17. W. Palinski, Immunomodulation: a new role for statins?, Nature Med. 6 (2000) 1311-1312.
18. J.A. Kobashigawa, S. Katznelson, H. Laks, J.A. Johnson, L. Yeatman, X.M. Wang, D. Chia, P.I. Terasaki, A. Sabad, G.A. Cogert, et al., Effect of pravastatin on outcomes after cardiac transplantation, N. Engl. J. Med. 333 (1995) 621-627.
19. A.P. Liappis, V.L. Kann, C.G. Rochester, G.L. Simon, The effect of statins on mortality in patients with bacteremia, Clin. Infect. Dis. 33 (2001) 1352-1357.
20. K.A. Mitropoulos, J.M. Armitage, R. Collins, T.W. Meade, B.E. Reeves, K.R. Wallendszus, S.S. Wilson, A. Lawson, R. Peto, Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables lipoproteins and free fatty acids. The Oxford cholesterol Study Group, Eur. Heart. J 18 (1997) 235-241.
21. T. Bourcier, P. Libby, HMG-CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells, Arterioscler. Thromb. Vasc. Biol. 20 (2000) 556-562.
22. S. Lopez, F. Peiretti, B. Bonardo, I. Juhan-Vague, G. Nalbone, Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type 1 in cultured human endothelial cells, Atherosclerosis 152 (2000) 359-366.
23. C. Klein-Soyer, J. Ceraline, C. Orvain, C. de la Salle, J.P. Bergerat, J.P. Cazenave, Angiogenesis inhibitor SR 25989 upregulates thrombospondin-1 expression in human vascular endothelial cells and foreskin fibroblasts, Biol. Cell 89 (1997) 295-307.